Pharmacology of Tyrosine Kinase Inhibitors: Implications for Patients with Kidney Diseases

Tyrosine kinase inhibitors (TKI) have introduced a significant advancement in cancer management. These compounds are administered orally, and their absorption holds a pivotal role in determining their variable efficacy. They exhibit extensive distribution within the body, binding strongly to both plasma and tissue proteins. Often reliant on efflux and influx transporters, TKI undergo primary metabolism by intestinal and hepatic cytochrome P450 enzymes, with non-kidney clearance being predominant. Due to their limited therapeutic window, many TKI display considerable intra- and interindividual variability. This review offers a comprehensive analysis of the clinical pharmacokinetics of TKI, detailing their interactions with drug transporters and metabolic enzymes, while discussing potential clinical implications. The prevalence of kidney conditions, such as acute kidney injury (AKI) and chronic kidney disease (CKD), among cancer patients is explored in terms of their impact on TKI pharmacokinetics. Lastly, the potential nephrotoxicity associated with TKI is also examined.

Mots clés

Tyrosine Kinase inhibitors pharmacokinetics drug-drug interactions cytochromes transporters kidney diseases metabolism Tyrosine Kinase inhibitors pharmacokinetics drug-drug interactions cytochromes transporters kidney diseases metabolism

Domaines

Sciences du Vivant [q-bio]

Fichier principal

PKPD.TKI.CJASN.subimission revised version 5_clean.pdf (631.45 Ko)

Origine	Fichiers produits par l'(les) auteur(s)

Mario Ollero : Connectez-vous pour contacter le contributeur

https://hal.u-pec.fr/hal-04347296

Soumis le : vendredi 15 décembre 2023-15:38:49

Dernière modification le : mercredi 30 octobre 2024-13:28:12

Dates et versions

hal-04347296 , version 1 (15-12-2023)

Identifiants

HAL Id : hal-04347296 , version 1
DOI : 10.2215/CJN.0000000000000395

Citer

Anne Hulin, Thibaut Gelé, Charlotte Fenioux, Emmanuelle Kempf, Dil Sahali, et al.. Pharmacology of Tyrosine Kinase Inhibitors: Implications for Patients with Kidney Diseases. Clinical Journal of the American Society of Nephrology, 2023, ⟨10.2215/CJN.0000000000000395⟩. ⟨hal-04347296⟩

Exporter

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

UNIV-PARIS13 IMRB UPEC LIMICS SORBONNE-UNIVERSITE SU-MEDECINE SU-SCIENCES SORBONNE-PARIS-NORD ACT-R

33 Consultations

163 Téléchargements